Primary source: Health Canada
Health Canada issued a recall for Cosyland Kids Kitchen Step Stools due to fall and entrapment hazards, requiring immediate cessation of use and provision of free repair parts.
The product poses serious risk of injury or death from tip-over, fall, or entrapment; similar products have caused injuries in the US.
Immediately stop using the recalled stools, store away from children, and contact Wan Yi (866-677-3889 / customerservice-ca@cosyland.com) to request free repair parts (protective nets, stabilizing feet, instructions).
Regulatory Intelligence Lead
Review in the next regulatory intelligence cycle.
Immediately stop using the recalled product and contact the manufacturer to receive free repair parts.
Immediately stop using the recalled stools, store away from children, and contact Wan Yi (866-677-3889 / customerservice-ca@cosyland.com) to request free repair parts (protective nets, stabilizing feet, instructions).
Health Canada published a recall alert for Cosyland Kids Kitchen Step Stools (model CS0003) sold on Amazon.ca. The stools can collapse or tip over, and openings allow torso entrapment. No incidents reported in Canada; 25 US incidents with 8 injuries reported. Consumers must stop use and contact Wan Yi for free repair parts (18 units sold in Canada).
What changed: Health Canada issued a recall for Cosyland Kids Kitchen Step Stools due to fall and entrapment hazards, requiring immediate cessation of use and provision of free repair parts.
Why it matters: The product poses serious risk of injury or death from tip-over, fall, or entrapment; similar products have caused injuries in the US.
Practical implication: Immediately stop using the recalled stools, store away from children, and contact Wan Yi (866-677-3889 / customerservice-ca@cosyland.com) to request free repair parts (protective nets, stabilizing feet, instructions).
Published from the Firecrawl agent regulatory extraction pipeline.
Implement a gap analysis for 505(b)(2) applications to identify safety data needs and adjust safety monitoring systems as necessary to accommodate new product characteristics.
MAHs and sponsors must enhance their pharmacovigilance systems to monitor microbiome-specific safety issues, comply with established safety standards, and address concerns related to antimicrobial resistance.
Stakeholders, including manufacturers and clinicians, must review and potentially revise their post-market vigilance and safety monitoring protocols in response to the FDA's proposed regulatory approaches for generative AI devices.
Developers of MBMPs must align their safety assessment protocols with the MHRA's expectations and are encouraged to engage with the MHRA early to establish appropriate regulatory strategies.
